It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Transaction Overview In January 2021, Rosetta Capital completed a secondary transaction to acquire a portfolio of seven life sciences assets from Schroder UK Public Private Trust plc, an large UK-based investment trust, for a total acquisition price of £49.0 million with an agreement to provide follow-on capital to support those companies through value creation. The …
Transaction Overview Rosetta Capital completed a secondary transaction to acquire a portfolio of over 20 North American and European life sciences assets from a Corporate Venture Capital arm of a Top 10 Pharma company. This enabled the Corporate Venture Capital arm to redeploy capital into assets that aligned strategically with the parent company. Selected exits …
Transaction Overview Rosetta Capital completed a secondary transaction involving debt and equity to secure a portfolio of US and Canadian life sciences assets from GrowthWorks, a Canadian fund manager. Selected exits from the portfolio include the sale of Gemin X to Cephalon, Ambit Pharmaceuticals to Daiichi Sankyo and Aegera to Pharmascience. All3 Exited Private Public …
Transaction Overview In February 2013, Rosetta Capital completed a secondary transaction to acquire a portfolio of thirteen life sciences assets from Karolinska Development, the investment arm of Karolinska Institutet, a leading university in Sweden. The sale portfolio consists of holdings in Akinion Pharmaceuticals, Aprea Therapeutics, Axelar, Biosergen, Clanotech, Dilafor, Inhalation Sciences, NeoDynamics, NovaSAID, Pergamum, Promimic, …
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
